Venus Concept Device Footprint: Venus Legacy, Viva, Bliss and the 2026 Go-Private Reset

Venus Concept (Toronto, Canada) is one of the most visible names in the medical aesthetics device market, particularly for clinics seeking multi-application radiofrequency (RF) and fractional skin resurfacing platforms. Their core systems—including Venus Viva, Venus Legacy, Venus Bliss, and the recently cleared Venus NOVA—are widely utilized by medical spas and dermatology practices for skin tightening, body contouring, and acne scar reduction.

However, for medical practitioners, business owners, and clinic directors evaluating a capital equipment purchase, Venus Concept represents a complex case study. In addition to reviewing clinical efficacy and regulatory clearances, buyers must navigate a rapid series of corporate restructurings. Over the last several years, Venus Concept has undergone a major reverse merger, divested its historical hair-restoration business, voluntarily delisted from the Nasdaq stock exchange, and transitioned to a private entity owned by its primary lender, Madryn Asset Management.

This guide provides a comprehensive analysis of Venus Concept’s regulatory footprint, compiles their complete FDA 510(k) clearances, analyzes post-market safety data from the FDA’s MAUDE database, details their recent corporate transition, and explains what this go-private reset means for providers who rely on their service contracts and clinical support.

---

What FDA clearances does Venus Concept hold for each platform?

Venus Concept has maintained a consistent regulatory pipeline since entering the U.S. market, securing approximately 22 aesthetic-relevant clearances since 2010. The company's technology is built primarily on its proprietary (MP)² (Multi-Polar Radiofrequency and Pulsed Electromagnetic Fields) and NanoFractional RF modalities.

In the standard FDA registry filtered to the 50 plastic-surgery product codes, Venus Concept holds 6 primary clearances:

1. Venus Versa (K152790) — Cleared 2016-01-20 (Product Code ONF)
2. Venus Versa System Expansion (K153717) — Cleared 2016-03-21 (Product Code ONF)
3. Venus Velocity Diode Laser (K162765) — Cleared 2017-01-11 (Product Code GEX)
4. Venus Epileve (K200786) — Cleared 2020-06-09 (Product Code GEX)
5. AI.ME System (K221011) — Cleared 2022-12-20 (Product Code QAI)
6. Venus Versa PRO System (K232192) — Cleared 2023-09-11 (Product Code ONF)

Expanding to the full openFDA database reveals the broader family of clearances that support the brand's legacy. The table below compiles the essential FDA clearances for Venus Concept's primary systems.

Technical Profiles of Core Venus Concept Technologies

Venus Concept’s clinical portfolio is built around three core modalities: Multi-Polar Radiofrequency, Pulsed Electromagnetic Fields, and NanoFractional RF. By analyzing the physical mechanisms of these technologies, providers can understand how each system performs in practice.

1. The (MP)² Technology Stack: Venus Legacy and Freeze Plus

The foundational technology for Venus Concept’s non-invasive skin tightening and wrinkle reduction is (MP)², which stands for Multi-Polar Radiofrequency and Pulsed Electromagnetic Fields.

• Multi-Polar RF: Unlike monopolar RF (which passes from a single active electrode to a grounding pad, heating deep tissue layers) or bipolar RF (which passes between two closely spaced electrodes, heating superficial layers), Venus Concept's multi-polar handpieces utilize a complex matrix of electrodes. The generator dynamically switches active pairs during treatment. This creates a highly uniform, rapidly shifting electromagnetic field that heats the dermal collagen layer to 39°C–42°C without creating hot spots or spikes. This thermal stimulus triggers immediate collagen contraction and initiates the long-term neocollagenesis cascade.
• Pulsed Electromagnetic Fields (PEMF): PEMF is a non-thermal energy modality that has been used in orthopedics for bone healing and wound management. When paired with RF, PEMF acts on the cellular level by stimulating the release of Fibroblast Growth Factor 2 (FGF-2). This growth factor induces the proliferation of dermal fibroblasts and triggers the formation of new microvascular networks (angiogenesis). The clinical goal is to improve tissue oxygenation, accelerate healing, and enhance the overall skin quality beyond what RF heating alone can achieve.
• VariPulse Integration: The Venus Legacy platform pairs the (MP)² energy stack with adjustable suction (VariPulse). The mechanical lymphatic massage helps release fluid retention, improves local circulation, and facilitates deeper penetration of the radiofrequency energy into the fibrotic septae of cellulite.

2. NanoFractional RF: Venus Viva and Viva MD

To address acne scars, striae (stretch marks), and deep textural irregularities, Venus Concept developed NanoFractional RF as a substitute for traditional fractional CO₂ or Erbium lasers.

• The Applicator Grid: The Venus Viva MD handpiece utilizes disposable tips containing up to 160 pin electrodes. Rather than using light energy to vaporize tissue, the system delivers radiofrequency energy through these microscopic pins, creating tiny columns of thermal ablation and coagulation in the epidermis and dermis.
• Ablation vs. Coagulation Control: The Viva MD allows the provider to adjust both the power (energy delivered per pin) and the pulse duration. This gives the clinician precise control over the ratio of ablation (tissue vaporization) to coagulation (heating without vaporization). For instance, active acne scars require a higher ablation ratio to break up fibrotic scar tissue, whereas superficial wrinkles are best treated with a higher coagulation ratio to preserve the epidermal barrier and reduce downtime.
• Downtime Comparison: Because the columns of injury are microscopic (typically under 150 microns in diameter) and are surrounded by healthy, untreated tissue, the healing process is rapid. Patients typically experience 24 to 48 hours of mild erythema, a significantly shorter recovery window compared to the 5 to 7 days required for fractional ablative lasers.

3. Diode Laser Lipolysis: Venus Bliss and Bliss MAX

For non-invasive body contouring and fat reduction, Venus Concept developed the Venus Bliss platform.

• 1060nm Diode Wavelength: The Bliss utilizes four hands-free laser applicators that emit light at the 1060nm wavelength. This specific wavelength targets the absorption spectrum of adipose tissue while minimizing absorption by the melanin and water in the overlying epidermis. The laser energy heats the subcutaneous fat layer to a target temperature of 42°C to 47°C, which triggers apoptosis (programmed cell death) in the fat cells. Over the subsequent 6 to 12 weeks, the body's lymphatic system processes and clears the damaged adipose cells.
• Contact Cooling: To protect the epidermis and maintain patient comfort during the 25-minute cycle, the applicators feature active contact cooling. The system alternates between heating cycles and cooling cycles to prevent thermal accumulation in the skin surface.
• Cellulite Targeting: The Bliss MAX variant pairs the 1060nm lipolysis applicators with the (MP)² RF handpiece, allowing the provider to treat fat reduction and skin laxity in the same patient. This is particularly useful for post-weight-loss contouring, where skin laxity frequently limits the aesthetic outcome of fat reduction alone.

4. Robotic Resurfacing: AI.ME System

The AI.ME System is Venus Concept’s high-precision fractional resurfacing platform.

• Robotic Guidance: Unlike manual fractional handpieces, which are highly operator-dependent and can suffer from uneven application or overlap burns, the AI.ME features an automated robotic scanning system. The handpiece tracks the skin surface and uses a motorized scanner to place the fractional energy columns in a precise, non-sequential pattern.
• Fractional Ablation: The robotic applicator delivers energy through micro-needles or fractional electrodes, automatically adjusting for skin curvature and impedance to ensure consistent depth of penetration. This is designed to improve clinical outcomes and reduce the risk of post-inflammatory hyperpigmentation (PIH) caused by manual over-treatment.

---

What is Venus Concept's MAUDE and recall record?

Understanding post-market clinical safety is critical for medical directors who assume clinical liability for treatments performed under their license. The FDA’s Manufacturer and User Facility Device Experience (MAUDE) database tracks complications, injuries, and device malfunctions reported after a system has entered clinical use.

MAUDE Adverse Event Summary

Analyzing the aesthetic-slice MAUDE registry reveals that Venus Concept has a moderate safety signal, with 11 brand-name adverse events recorded.

The events are distributed across the following device categories:

• Venus Bliss / Bliss Max: 4 reports (filed under product code PKT / ORK)
• Venus Viva / Viva MD: 2 reports (filed under product code GEI / GEX)
• Venus Velocity / Epileve: 2 reports (filed under product code GEX)
• Venus Versa / System: 2 reports (filed under product code ONF)
• Venus Concept general string: 1 report

Of these 11 reports, 9 were classified as Patient Injuries and 2 as Device Malfunctions. By FDA product code, the events fall under PKT (4 reports — the lipolysis-laser code used by Venus Bliss / Bliss Max), ONF (4 — the IPL code used by Venus Versa), GEX (2 — Venus Velocity / Epileve), and ORK (1). In other words, the safety signal sits with the higher-energy 1060 nm laser, IPL, and fractional-RF applicators, not with the low-energy (MP)² skin-tightening handpieces.

The MAUDE summary record lists event type, product code, and brand, but it does not publish full clinical narratives. Read against the device classes involved, the two risks that matter for these modalities are well established in the energy-device literature: thermal injury (burns) when a 1060 nm lipolysis or fractional-RF applicator delivers excessive energy or stacked pulses, and post-inflammatory hyperpigmentation (PIH) — the dominant safety concern for Fitzpatrick skin types IV through VI. These are the same failure modes that drive Venus Concept’s published provider protocols around continuous skin-contact maintenance, temperature monitoring, and matching energy settings to the patient’s Fitzpatrick type.

Recall Compliance Record

A query of the FDA Recall Database shows zero active recalls for Venus Concept’s primary aesthetic line (Venus Legacy, Viva, Bliss, Versa, Velocity, Epileve, and AI.ME). The company has maintained basic regulatory compliance regarding manufacturing standards and quality control systems, avoiding the large-scale Class I or Class II recalls that have historically impacted some laser and breast implant manufacturers.

---

What happened to Venus Concept in 2025-2026?

While Venus Concept's regulatory clearances have remained stable, its corporate structure has undergone a dramatic transformation. Medical directors and business operators must understand this transition, as it directly impacts the long-term support, warranty enforcement, and service network of the equipment.

1. The Reverse Merger and the Hair Restoration Divestiture

In 2019, Venus Concept transitioned to a public listing on the Nasdaq exchange (under ticker VERO) via a reverse merger with Restoration Robotics, the manufacturer of the ARTAS robotic hair-restoration system. This merger combined Venus Concept's radiofrequency platforms with Restoration Robotics' automated hair transplantation technology (ARTAS and NeoGraft).

However, managing a high-capital robotic hair business alongside a high-volume aesthetic RF business created operational friction. In late 2024, Venus Concept entered into a definitive agreement to sell its entire hair-restoration business (NeoGraft and ARTAS) to Meta Healthcare Group (a Korean-aligned wellness entity) for $20 million. This divestiture allowed Venus Concept to return to its core competency: manufacturing and supporting multi-polar RF, fractional RF, and non-invasive body contouring platforms.

2. The Nasdaq Delisting (January - February 2026)

Facing prolonged capitalization challenges and failing to meet the minimum bid price requirements of the Nasdaq exchange, Venus Concept’s Board of Directors elected to restructure the company’s capital.

On or about January 30, 2026, Venus Concept filed Form 25 with the Securities and Exchange Commission (SEC) to voluntarily delist its common stock from the Nasdaq. The last official trading day for VERO stock occurred on or about February 6, 2026. Following the delisting, the company deregistered its shares, ending its obligations as a publicly traded reporting entity.

3. The Madryn Go-Private Merger (March 30, 2026)

The final stage of the corporate transition was completed on March 30, 2026 (publicly announced on April 1, 2026). Madryn Asset Management, Venus Concept's primary secured lender, acquired all remaining outstanding shares of common stock not already held by Madryn or its affiliates.

This transaction was executed as a short-form merger under Delaware law at a purchase price of $0.04 per share in cash. Upon completion of this merger:

• Venus Concept became a wholly privately held company.
• Madryn Asset Management assumed complete ownership and control of the entity.
• A new executive leadership structure was finalized, led by CEO Rajiv De Silva.

4. The 2026 Operational Focus: Venus NOVA and the GLP-1 Market

With its debt restructured and the hair business divested, Venus Concept’s private management pivot is centered on the Venus NOVA platform, which secured FDA 510(k) clearance on November 6, 2025 (publicly announced November 10).

NOVA is a multi-application platform that combines Adaptive Electrical Muscle Stimulation (EMS), Multi-Polar RF, Pulsed Electromagnetic Fields (PEMF), and VariPulse technology in a single system. Under Chief Product Officer Melissa Kang, Venus Concept is explicitly positioning the NOVA platform to address the growing post-GLP-1 weight-loss market. As patients experience rapid volume loss from semaglutide or tirzepatide treatments, they frequently experience skin laxity and muscle mass loss. Venus Concept’s post-GLP-1 positioning combines RF skin tightening with electrical muscle stimulation to rebuild muscle tone and tighten tissue, establishing a clear clinical pathway for clinics managing medical weight loss patients.

---

What does the go-private reset mean for providers?

For medical spa owners and clinical directors, a manufacturer transitioning from public to private ownership introduces specific operational risks and opportunities.

Potential Benefits for Providers

• Operational Focus: Now free from the quarterly earnings pressure of public markets and the high cost of SEC compliance, Venus Concept can focus its capital on product engineering, clinical training, and local service support.
• Stable Financial Backing: Madryn Asset Management is an established healthcare-focused private equity firm. Their direct ownership provides Venus Concept with a more stable capital structure compared to its final years as a distressed public penny stock.
• Simplified Product Line: Divesting the complex ARTAS robotic hair systems means the field service engineers can focus entirely on supporting the RF, IPL, and body contouring platforms.

Operational Risks to Manage

• Warranty Enforcement: While Madryn has committed to honoring existing service agreements, providers should audit their active contracts. If a clinic operates a legacy system (such as the early Freeze or early-model Legacy), parts availability may decline as the company prioritizes the newer Versa PRO and NOVA lines.
• ARTAS and NeoGraft Support: Clinics that purchased ARTAS or NeoGraft systems prior to 2025 must redirect their service calls, consumable purchases, and training needs to Meta Healthcare Group (MHG), which now owns and supports those product lines. Venus Concept's field service network no longer supports these hair-restoration systems.
• Service Network Consolidation: Private equity ownership frequently drives cost consolidation. Providers should expect potential transitions in their local sales representation and field service territories, which can impact response times for system repairs.

---

How does Venus Concept compare with InMode and BTL?

For practices evaluating a multi-application platform, Venus Concept sits in a competitive triangle with InMode and BTL Aesthetics.

Feature Comparison Matrix: Multi-App Platforms

[VENUS CONCEPT (Versa PRO / NOVA)]
- Primary Energy Stack: Multi-Polar RF + PEMF + Fractional RF + EMS + IPL
- Clinical Focus: Superficial skin tightening, lymphatic drainage, fractional ablation, IPL rejuvenation
- Hands-Off Options: Monopolar RF / EMS applicators (NOVA)
- Corporate Structure: Private (Owned by Madryn Asset Management)

[INMODE (Aesthetic Platform / Optimax)]
- Primary Energy Stack: Bipolar RF + Microneedling RF + IPL + Diode Laser
- Clinical Focus: Subdermal adipose coagulation (Morpheus8), deep structural remodeling, vascular/hair clearing
- Hands-Off Options: Evoke (facial remodeling), EvolveX (body remodeling)
- Corporate Structure: Publicly Traded (NASDAQ: INMD)

[BTL AESTHETICS (Emsculpt Neo / Emface / Exion)]
- Primary Energy Stack: HIFEM / HIFES + Monopolar RF + Targeted Ultrasound
- Clinical Focus: Deep muscle stimulation (skeletal/facial), pelvic health, targeted RF remodeling
- Hands-Off Options: Completely hands-off (Emsculpt/Emface pads, Emsella chair)
- Corporate Structure: Private (BTL Industries)

Key Decision Rules for Providers

• Choose Venus Concept if: Your practice requires a reliable, entry-level multi-app platform (Versa PRO) that combines high-quality IPL with gentle, non-painful skin tightening (Multi-Polar RF + PEMF). The (MP)² technology is highly tolerated by patients and is excellent for facial lymphatic drainage and superficial wrinkle management. Additionally, if you are building a post-GLP-1 body contouring protocol, the new Venus NOVA platform offers a well-integrated RF + EMS combination.
• Choose InMode if: Your focus is on deep, subdermal adipose tissue remodeling and invasive fractional resurfacing. The InMode RF platform (featuring Morpheus8) delivers higher peak energy and targets deeper fascial planes, but carries higher patient discomfort and requires hands-on operator time.
• Choose BTL Aesthetics if: Your clinic prioritizes hands-off labor utilization and skeletal muscle development. Platforms like Emsculpt Neo and Emface utilize electromagnetic stimulation (HIFEM/HIFES) to build muscle tone in a way that radiofrequency alone cannot, though at a significantly higher capital acquisition cost.

---

Frequently Asked Questions

Is Venus Concept still a public company after 2026?

No. Venus Concept voluntarily delisted from the Nasdaq stock exchange in February 2026. On March 30, 2026, it completed a short-form merger with its primary secured lender, Madryn Asset Management, at $0.04 per share. It is now a wholly privately held company owned and controlled by Madryn.

Is the Venus NOVA FDA-cleared, and what is it cleared for?

Yes, Venus NOVA received FDA 510(k) clearance on November 6, 2025 (K252845, announced November 10). It is cleared as a multi-application platform that combines Adaptive Electrical Muscle Stimulation (EMS), Multi-Polar RF, Pulsed Electromagnetic Fields (PEMF), and VariPulse. It is indicated for non-invasive wrinkle treatment, temporary reduction of cellulite, and muscle stimulation.

Did Venus Concept sell its ARTAS and NeoGraft hair-restoration business?

Yes. In late 2024, Venus Concept sold its entire hair-restoration division (including the ARTAS robotic hair transplant system and NeoGraft automated follicular unit extraction system) to Meta Healthcare Group for $20 million. Venus Concept no longer manufactures, sells, or services these hair-restoration platforms.

---

Sources

1. FDA 510(k) Database (Venus Viva): U.S. Food and Drug Administration. 510(k) Summary K191065 for Venus Viva.
2. FDA 510(k) Database (Venus Viva MD): U.S. Food and Drug Administration. 510(k) Summary K201164 for Venus Viva MD.
3. FDA 510(k) Database (Venus Versa PRO): U.S. Food and Drug Administration. 510(k) Clearance K232192 for Venus Versa PRO System.
4. Venus NOVA FDA Clearance Announcement: Venus Concept. Venus Concept Receives FDA 510(k) Clearance for Venus NOVA. November 10, 2025. Investor Relations Release.
5. Madryn Go-Private Merger Announcement: Venus Concept. Venus Concept Announces Completion of Common Stock Sale and Short-Form Merger. April 1, 2026. Nasdaq / Press Release.
6. Venus Hair Business Sale: Venus Concept. Venus Concept Announces Definitive Agreement to Sell Venus Hair Restoration Business. Investor Relations Release.
7. RF and PEMF Efficacy Study: Gold MH, et al. Evaluation of the safety and efficacy of a multi-polar radiofrequency and pulsed electromagnetic field device for the treatment of facial wrinkles and skin laxity. Journal of Clinical and Aesthetic Dermatology. 2020;13(6):18-22.